Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor

Vaccine

Volumn 28, Issue 44, 2010, Pages 7193-7201

  Chu, Chia ^a,b   Lugovtsev, Vladimir ^c   Lewis, Andrew ^c   Betenbaugh, Michael ^b   Shiloach, Joseph ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b Johns Hopkins University   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Anchorage independent; Hemagglutinin; Mammalian cell line; Vaccine

Indexed keywords

INFLUENZA VACCINE; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ARTICLE; BIOREACTOR; CELL STRAIN; HEMAGGLUTINATION INHIBITION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; KIDNEY CELL; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROGENY; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STIRRED REACTOR; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, VIRAL; BIOREACTORS; CELL LINE; CHICKENS; DOGS; FEMALE; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; MICE; MICE, NUDE; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 77957822721     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.059     Document Type: Article

References (24)

1. Stohr K., Esveld M. Will vaccines be available for the next influenza pandemic?. Science 2004, 306(December (5705)):2195-2196.
2. Temte J.L. Preparing for an influenza pandemic: vaccine prioritization. Fam Pract Manage 2006, 13(January (1)):32-34.
3. Schwartz B., Orenstein W.A. Prioritization of pandemic influenza vaccine: rationale and strategy for decision making. Curr Top Microbiol Immunol 2009, 333:495-507.
4. Minor PD. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin Infect Dis 2010; Feb 15;50(4):560-5.
5. Barrett P.N., Mundt W., Kistner O., Howard M.K. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009, 8(May (5)):607-618.
6. Tosh P.K., Poland G.A. Emerging vaccines for influenza. Expert Opin Emerg Drugs 2008, 13(March (1)):21-40.
7. Tree J.A., Richardson C., Fooks A.R., Clegg J.C., Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 2001, 19(May (25-26)):3444-3450.
8. Youil R., Su Q., Toner T.J., Szymkowiak C., Kwan W.S., Rubin B., et al. Comparative study of influenza virus replication in Vero and MDCK cell lines. J Virol Methods 2004, 120(September (1)):23-31.
9. Merten O.W., Manuguerra J.C., Hannoun C, van der Werf S Production of influenza virus in serum-free mammalian cell cultures. Dev Biol Stand 1999, 98:23-37. discussion 73-4.
10. Audsley J.M., Tannock G.A. The role of cell culture vaccines in the control of the next influenza pandemic. Expert Opin Biol Ther 2004, 4(May (5)):709-717.
11. Genzel Y., Olmer R.M., Schafer B., Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 2006, 24(August (35-36)):6074-6087.
12. Hu A.Y., Weng T.C., Tseng Y.F., Chen Y.S., Wu C.H., Hsiao S., et al. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines. Vaccine 2008, 26(October (5)):5736-5740.
13. Chu C., Lugovtsev V., Golding H., Betenbaugh M., Shiloach J. Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production. Proc Natl Acad Sci USA 2009, 106(September (35)):14802-14807.
14. Lewis A.M., Alling D.W., Banks S.M., Soddu S., Cook J.L. Evaluating virus-transformed cell tumorigenicity. J Virol Methods 1999 Apr, 79(1):41-50.
15. Lugovtsev V.Y., Vodeiko G.M., Levandowski R.A. Mutational pattern of influenza B viruses adapted to high growth replication in embryonated eggs. Virus Res 2005, 109(May (2)):149-157.
16. Robertson J.S. Clinical influenza-virus the embryonated hens egg. Rev Med Virol 1993, 3(June (2)):97-106.
17. Audsley J.M., Tannock G.A. Cell-based influenza vaccines: progress to date. Drugs 2008, 68(11):1483-1491.
18. Merten O.W., Hannoun C., Manuguerra J.C., Ventre F., Petres S. Production of influenza virus in cell cultures for vaccine preparation. Adv Exp Med Biol 1996, 397:141-151.
19. Kessler N., Thomas-Roche G., Gerentes L., Aymard M. Suitability of MDCK cells grown in a serum-free medium for influenza virus production. Dev Biol Stand 1999, 98:13-21. discussion 73-4.
20. Doroshenko A., Halperin S.A. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009, 8(June (6)):679-688.
21. Jaluria P., Betenbaugh M., Konstantopoulos K., Frank B., Shiloach J. Application of microarrays to identify and characterize genes involved in attachment dependence in HeLa cells. Metab Eng 2007, 9(May (3)):241-251.
22. Hossain M.J., Mori I., Dong L., Liu B., Kimura Y. Fetal calf serum inhibits virus genome expression in Madin-Darby canine kidney cells persistently infected with influenza A virus. Med Microbiol Immunol 2008, 197(March (1)):21-27.
23. Mori S., Chang J.T., Andrechek E.R., Matsumura N., Baba T., Yao G., et al. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 2009, 28(August (31)):2796-2805.
24. Cifone M.A., Fidler I.J. Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA 1980, 77(February (2)):1039-1043.